VHL
12 articles
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Ugi chemistry turns ligand libraries into PROTACs for target-agnostic screening
- A one-pot Ugi multicomponent reaction joins carboxylic-acid ligands to VHL ligand–linker conjugates in a single plate step, with solid-phase clean-up before cell assays.
- A pilot library from seven diverse ligands was screened phenotypically in six cancer lines with no target chosen in advance.
- Proteomics traced the best hit, a BI2536-derived degrader, to BRD4 degradation with clear selectivity over PLK1; NanoBRET and modeling supported ternary complex formation.
- Ugi-built photoaffinity probes confirmed BRD4 as the direct binding partner.
This flips the usual PROTAC workflow: degradation phenotype first, target second. The catch is the Ugi linker, which is stubby and amide-rich compared with optimized PROTAC linkers, so hits will likely be under-potent for many ligand classes. I'd feed it our orphan-ligand collection, then re-linker the survivors by conventional SAR.
Medicinal ChemistryBioorganic & Medicinal Chemistry
Aptamer-linked JQ1 conjugates offer a cell-free way to compare E2/E3 ubiquitination of BRD4
- JQ1 was attached by click chemistry to a DNA aptamer that binds His tags, so any His-tagged E3 can be recruited to BRD4 without custom ligands.
- In a reconstituted system, the conjugates drove BRD4 polyubiquitination with VHL complex, with a drop at high dose consistent with a hook effect.
- Different E3 and E2 combinations gave distinct ubiquitin patterns; lysine-free ubiquitin and conjugate length helped separate chain growth from multi-site modification.
As a tool compound this is attractive: swapping E3 ligands for a His-tag handle makes E3 comparisons ligand-free and clean. But a cell-free readout with a big DNA linker says little about real degraders, where ternary-complex geometry, permeability and linker length drive degradation. Next step: benchmark against a matched JQ1–VHL PROTAC (e.g., MZ1) in the same assay to see whether ubiquitination patterns track cellular DC50.
Medicinal ChemistryEuropean Journal of Medicinal Chemistry
Entinostat-based PROTACs preferentially degrade HDAC3 in colorectal cancer models
- Two PROTAC series were built on the HDAC inhibitor entinostat, recruiting either VHL or CRBN E3 ligases.
- A representative from each series drove time-dependent HDAC loss, favouring HDAC3, followed by apoptosis and lower viability in colorectal cancer models.
- Activity was tested in patient-derived organoids and a CAM model, with p21 and the stemness markers CD44 and LGR5 probing acetylation-driven gene regulation.
Preferential HDAC3 loss may partly reflect the entinostat warhead's own isoform profile, so the first things to look for are a non-binding or inactive-epimer control and a way to separate degradation from inhibition, such as HDAC3 knockout or proteasome and neddylation blockade. A comparison with other HDAC3-selective PROTACs would also show whether the VHL versus CRBN choice shapes isoform bias.
Medicinal ChemistryEuropean Journal of Medicinal Chemistry (Elsevier)
VHL-based PROTACs turn a pan-FGFR inhibitor into FGFR2/4-selective degraders
- The team linked an in-house pan-FGFR inhibitor to a VHL ligand, building a PROTAC series.
- Two lead compounds degraded FGFR2 and FGFR4 selectively through the ubiquitin-proteasome system and showed potent antiproliferative effects in cells.
- In a gastric cancer xenograft model they shrank tumors with target degradation, and ternary complex modeling rationalized the isoform selectivity. The authors describe these as the first FGFR4-directed PROTACs.
A pan-FGFR warhead yielding FGFR2/4-selective degraders is the real story: degradation selectivity comes from ternary-complex geometry, not binding affinity, so the SAR lives in the linker and VHL exit vector. FGFR4 has been mostly covalent-inhibitor territory, so this is a genuinely different handle. I'd check FGFR1/3 sparing and hook effect.
Medicinal ChemistryACS Chemical Biology
Why BRD9 PROTACs underperform in mice, and a humanized-E3 fix
- Widely used CRBN- and VHL-based BRD9 degraders such as dBRD9 and VZ185 are much less potent in mouse cells, even though BRD9 itself is highly conserved.
- The gap points to species differences in the E3 ligases, notably the Crbn I391 residue and structural variation in VHL, which likely hamper ternary complex formation.
- Expressing human CRBN or VHL, or introducing a CrbnI391V mutation, restored potency in mouse cells and improved BRD9 degradation in vivo.
Anyone who has watched a PROTAC look great in human lines and flat in a mouse efficacy study will recognize this. It is a reminder that degrader PK/PD in rodents can fail for E3 reasons rather than compound reasons, so a CrbnI391V or humanized-E3 model is worth setting up early. It also argues for profiling ternary complex formation across species before reading a negative in vivo result as a dead series.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Much of the PROTAC target-engagement spread is exposure, not E3 recognition
- Twenty PROTACs with varied E3 ligands, linkers and target binders were profiled in intracellular NanoBRET competition assays against cereblon and VHL tracers.
- Apparent potency spread widely when referenced to applied concentration, and passive Caco-2 permeability explained little of it.
- Correcting for measured intracellular unbound exposure shrank the spread dramatically, matching values from permeabilized cells.
Before I read a PROTAC SAR table as E3 affinity, I'd now ask what the cell actually saw. If most of the shift is unbound exposure, linker tweaks that look like potency gains may just be permeability gains, and measuring exposure early keeps us from chasing the wrong variable.
Medicinal ChemistrychemRxiv
Longer semi-rigid linkers drive VHL-based HDAC6 degraders with antileukemic activity
- A solid-phase route enabled systematic variation of VHL ligand, exit vector and linker in vorinostat-derived HDAC6 PROTACs.
- Longer, semi-rigid linkers gave the best degradation; the lead compounds degraded HDAC6 preferentially in MM.1S and MV4-11 cells.
- A matched non-degrading control with similar HDAC inhibition was clearly less antiproliferative, pointing to degradation itself as the driver.
The non-degrading control with matched enzyme inhibition is the kind of experiment that separates degradation from plain inhibition, and it favors the PROTAC. Preferential, not exclusive, HDAC6 selectivity from a vorinostat-like warhead is the weak point; a more isoform-selective ligand might sharpen it.
Medicinal ChemistrychemRxiv
Can ternary-complex scoring rank close PROTAC linker analogues? A matched-pose test
- Linker optimization in targeted protein degradation is still largely empirical.
- The preprint asks whether current computational methods can rank close linker analogues before synthesis, the finest chemical differences yet tested.
- It uses a matched-pose design on VHL-recruiting SHP2 degraders to isolate the effect of the linker.
- This is a preprint, not yet peer reviewed; the snippet-level abstract available limits detail on the outcome.
Linker tweaks are where PROTAC campaigns burn months of synthesis, so an honest test of whether scoring can separate near-identical analogues is more useful than another headline-grabbing benchmark. Matched poses remove the usual excuse that the method just got the geometry wrong. Even a negative answer helps: it tells us to keep building degradation and cooperativity assays rather than trusting a docked score.
Medicinal ChemistryJournal of the American Chemical Society (ACS)
BmTACs Ride Age-Upregulated Transcytosis to Deliver a ROS-Activated DAPK1 Degrader into the Brain
- Brain delivery is the main barrier for degraders in neurodegeneration; BmTACs attach a macrocyclic peptide shuttle that exploits caveolae-mediated transcytosis, which rises with age in brain endothelium.
- A reactive-oxygen-species-responsive cage on the VHL ligand keeps the PROTAC inactive until it reaches high-ROS tissue.
- The platform is designed to remove activated DAPK1 selectively in the aging brain.
Two gating layers, shuttle for entry and ROS cage for activation, is clever systems design, but it moves the problem from medicinal chemistry to conjugate CMC and PK. I'd look hard at the unmasked-PROTAC fraction in periphery and at the shuttle's dependence on aged-endothelium biology, which could narrow the patient window. A real step for CNS degraders if the in vivo data hold up.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Novel VHL-Recruiting PROTACs Degrade Mutant EGFR and Show Efficacy in NSCLC Models
- Researchers designed VHL-recruiting PROTAC degraders targeting EGFR, aiming to overcome acquired resistance to conventional EGFR kinase inhibitors in non-small cell lung cancer (NSCLC).
- Lead compounds C4 and D4 achieved potent, selective, and durable degradation of the EGFR Del19 and L858R resistance mutants.
- C4 induced cell cycle arrest and apoptosis, showed subnanomolar antiproliferative activity, and produced significant tumor regression in an HCC827 xenograft model at low intravenous doses on a reduced twice-weekly schedule.
- D4 was orally bioavailable and blood-brain barrier penetrant, and oral dosing completely halted tumor growth in vivo.
- The findings support a degradation-based strategy, rather than conventional inhibition, as a route to next-generation EGFR-directed therapies with potential central nervous system relevance.
D4 clearing both the oral bioavailability and blood-brain-barrier bars is the real headline here, more than the VHL-EGFR chemistry itself — most VHL degraders are 800-1000 Da PEG-linked bricks, gorgeous in a dish, DOA as an oral CNS drug. That's the developability wall this class has been stuck at. C4's profile reads more like a conventional IV PROTAC: subnanomolar antiproliferative potency and regression at low twice-weekly doses is a solid therapeutic index, but the reduced dosing schedule signals they're still managing catalytic turnover and clearance, not solving it outright. Degrading Del19/L858R instead of inhibiting them sidesteps the secondary-mutation resistance that keeps eroding osimertinib responses. If selectivity holds against WT EGFR in vivo, this is a real next-gen chemotype for NSCLC, not just a mechanistic proof-of-concept.
Medicinal ChemistryJournal of the American Chemical Society (ACS)
Antibody-Guided PROTAC Conjugate Blocks Tumor-Stroma Crosstalk by Silencing Extracellular Vesicles
- Researchers built Ctx-ETAC, a degrader-antibody conjugate pairing the approved EGFR antibody cetuximab with an engineered PROTAC payload, attached via a bioorthogonal reaction at a defined, controlled ratio per antibody.
- Its PROTAC payload pairs an indomethacin-derived COX-2 ligand with a VHL-recruiting peptide via a cathepsin B-cleavable linker, releasing the degrader selectively inside EGFR-positive tumor cells and activated fibroblasts.
- Degrading COX-2 in both cell types substantially curtails extracellular vesicle secretion, severing a key tumor-stroma signaling channel and nudging fibroblasts toward a quiescent, less tumor-supportive state.
- In a lung cancer xenograft model, Ctx-ETAC outperformed cetuximab alone in restraining tumor growth without added systemic toxicity, supporting microenvironment-targeted degradation as a therapeutic strategy.
Finally, a DAC that isn't just "ADC with a cooler payload" — swapping a cytotoxin for a VHL-PROTAC means efficacy doesn't hinge on brute-force poisoning of every internalized antibody; you get catalytic, event-driven target destruction instead. Smart target choice: COX-2 isn't the oncogenic driver, it's stromal plumbing. Cutting EV secretion to defuse tumor-fibroblast crosstalk instead of chasing EGFR resistance mutations directly is a genuinely different SAR logic than the usual "degrade the driver" playbook. Chemistry-wise, nothing exotic — indomethacin-COX-2 ligand, VHL peptide, cathepsin B-cleavable linker, defined-DAR bioorthogonal attachment. That's the point: boringly tractable, which is exactly what a translatable conjugation platform should look like. Real question is whether COX-2/EV silencing holds up in a fibroblast-rich, resistant tumor, not just a clean xenograft — but as a proof that microenvironment-directed degradation is maturing past a concept, this is convincing.
Medicinal ChemistryJournal of the American Chemical Society (ACS)
Cyclic Peptide PROTACs Knock Down HIF-1α — Until Hypoxia Outpaces Them
- Custom bifunctional amino acids — carrying a VHL-recruiting ligand and a variable linker — are incorporated directly during solid-phase peptide synthesis, an alternative to conventional PEG-based linkers for building cyclic peptide degraders.
- A SICLOPPS-derived cyclic peptide HIF-1 inhibitor serves as the warhead, yielding cyclic peptide PROTACs (CP-PROTACs) that engage VHL in a productive ternary complex.
- The degraders lower HIF-1α levels and hypoxia-response signaling across multiple cancer cell lines.
- Degradation is oxygen-state dependent — robust under moderate hypoxia but largely lost under more severe hypoxia, even though the degrader still engages and marks HIF-1α there.
- The activity loss reflects a kinetic mismatch, not a binding failure: HIF-1α resynthesis outpaces degradation, pointing to a general ceiling on PROTAC efficacy against rapidly replenished targets.
Smart move folding the VHL ligand and linker into a bifunctional amino acid for direct SPPS incorporation — that sidesteps the PEGylation/conjugation bottleneck that makes cyclic peptide degraders such a pain to iterate on, and it turns linker SAR into a synthesis-cycle variable instead of a separate coupling step. The SICLOPPS-derived warhead is a nice proof that a cyclic peptide can grip a transcription-factor surface a small molecule can't easily touch, so on chemotype comparison this favors the peptide side. But the real flag for my own work is the hypoxia dropout: ternary complex still forms, HIF-1α still gets marked, degradation just can't keep up. That's not a binding problem I'd fix by optimizing the VHL warhead — it's a turnover-rate problem, and it says something uncomfortable about any PROTAC campaign against a target with fast resynthesis kinetics.